

## 2024 Financial Statements

These figures are extracted from the complete annual report 2024 of Stichting International Kidney Cancer Coalition in Utrecht, Netherlands as determined by the Board on 12<sup>th</sup> March 2025.

This annual report has been provided with an unqualified auditor's report, by Van Hoesel/De Blaey Accountancy B.V. on 12<sup>th</sup> March 2025.

*Anne Wilson*

Anne Wilson  
Secretary/Treasurer

**2. FINANCIAL STATEMENTS**

## Stichting International Kidney Cancer Coalition

### 2.1. Balance sheet as of 31 December 2024

(After appropriations of results)

	<b>31 December 2024</b>		<b>31 December 2023</b>	
<b>ASSETS</b>	€	€	€	€
<b>Current Assets</b>				
<i>Receivables</i>				
Other prepayments and accrued income	67,725		3,006	
		67,725		3,006
<i>Securities</i>		682,367		637,822
<i>Cash at bank and in hand</i>		450,259		729,488
<b>Total assets</b>		<b>1,200,351</b>		<b>1,370,316</b>

## Stichting International Kidney Cancer Coalition

### 2.1. Balance sheet as of 31 December 2024

(After appropriations of results)

<b>LIABILITIES</b>	<b>31 December 2024</b>		<b>31 December 2023</b>	
	€	€	€	€
<b>Equity capital</b>				
Restricted reserves	453,711		535,000	
Unrestricted reserves	658,526		774,167	
		1,112,237		1,309,167
<b>Current liabilities</b>				
Accounts payable	60,321		33,279	
Accruals and other payables	27,793		27,870	
		88,114		61,149
<b>Total liabilities</b>		<b>1,200,351</b>		<b>1,370,316</b>

## Stichting International Kidney Cancer Coalition

### 2.2. Statement of income and expenditure 2024

	<b>2024</b>	<b>2023</b>
	€	€
Income	620,175	816,613
Expenditure	882,049	831,126
<b>Operating result</b>	<b>(261,874)</b>	<b>(14,513)</b>
Financial income & (expenses)	64,944	37,429
<b>Result for the year</b>	<b>(196,930)</b>	<b>22,916</b>

The amendment of reserves is divided as follows

Restricted reserves World Kidney Cancer Day	(126,689)	(197,067)
Restricted reserves Global Kidney Cancer Summit	(142,375)	(157,220)
Restricted reserves PAG Incubator	--	--
Restricted reserves Dashboard Project	(1,694)	(2,214)
Restricted reserves Global Patient Survey	--	(8,375)
Restricted reserves Decision Aid: Best Supportive Care	(25,660)	(26,184)
Restricted reserves Clinical Leadership Develop. Workshop	(20,171)	(12,729)
Restricted reserves Kidney Cancer Advocacy Feas. Study	--	(3,365)
Restricted reserves Global Patient Survey 2024	(107,605)	--
Restricted reserves CAB	--	--
Restricted reserves Seed and Grow	(2,241)	--
Restricted reserves SDM Analysis 2024	(14,457)	--
Restricted reserves RCC Perisurgical TC (RCC-PTC) meeting 2024	--	--
Restricted reserves Interact Europe 100	--	--
Restricted reserves DISCERN	(1,246)	--
Restricted reserves CARE1	(3,824)	--
The addition to the unrestricted reserves	249,032	430,070
<b>Result for the year</b>	<b>(196,930)</b>	<b>22,916</b>

## Stichting International Kidney Cancer Coalition

### 2.3. Cash flow statement 2024

The cash flow statement has been prepared according to the indirect method.

	<b>2024</b>	<b>2023</b>
	€	€
<b>Cash flow from operating activities</b>		
<b>Result for the year</b>	<b>(196,930)</b>	<b>22,916</b>
<i>Adjustments for:</i>		
Financial (income) and expenses	(64,944)	(37,429)
<b>Operating result</b>	<b>(261,874)</b>	<b>(14,513)</b>
<i>Change in working capital:</i>		
(Increase) / decrease in receivables	(64,719)	59,068
Increase / (decrease) in current liabilities	26,965	(68,755)
<b>Cash generated from operations</b>	<b>(299,628)</b>	<b>(24,200)</b>
Interest received from bank accounts	957	1,325
<b>Net cash generated from operating activities</b>	<b>(298,671)</b>	<b>(22,875)</b>
<b>Cash from investing activities</b>		
Additions to the investment account	--	(150,000)
<b>Net cash from investing activities</b>	<b>--</b>	<b>(150,000)</b>
<b>Net cash flow</b>	<b>(298,671)</b>	<b>(172,875)</b>
Exchange gains and (losses) on cash and cash equivalents	19,442	(19,226)
<b>Net (decrease) in cash and cash equivalents</b>	<b>(279,229)</b>	<b>(192,101)</b>
Cash and cash equivalents at the beginning of the year	729,488	921,589
<b>Cash and cash equivalents at the end of the year</b>	<b>450,259</b>	<b>729,488</b>

## 2.4. Notes to the financial statements

### General notes

#### Activities

The activities of Stichting International Kidney Cancer Coalition, having its registered office at Ouder-Amstel primarily consist of:

- The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

#### Registered office, legal form and registration number at the chamber of commerce

Stichting International Kidney Cancer Coalition has been registered at the Chamber of Commerce under file number 62070665.

#### Estimates

In applying the principles and policies for drawing up the financial statements, the management of the IKCC makes different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under art. 362, sub-1, book 2 of the Dutch Civil Code the nature of these estimates and judgments, including related assumptions, is disclosed in the Notes to the relevant financial statement item.

#### Accounting policies for the cash flow statement

The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flows denominated in foreign currencies have been translated at average estimated exchange rates. Exchange differences affecting cash items are shown separately in the cash flow statement. Interest paid and received, dividends received and income taxes are included in cash from operating activities. Dividends paid are recognised as cash used in financing activities. The purchase consideration paid for the acquired group company has been recognised as cash used in investing activities where it was settled in cash. Any cash at bank and in hand in the acquired group company have been deducted from the purchase consideration. Transactions not resulting in inflow or outflow of cash, including finance leases, are not recognised in the cash flow statement. The value of the related asset and lease liability are disclosed in the notes to the balance sheet items. Payments of finance lease instalments qualify as repayments of borrowings under cash used in financing activities and as interest paid under cash generated from operating activities.

### General accounting policies

#### General

The financial statements are drawn up in accordance with the Richtlijnen voor de Jaarverslaggeving C1 Kleine Organisaties-zonder-winststreven (RJK C1). The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model. Income and expenditure are allocated to the year to which they are related. Results are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

#### Comparison with previous year

The valuation principles and method of determining the result are the same as those used in the previous year, with the exception of the changes in accounting policies as set out in the relevant sections.

# Stichting International Kidney Cancer Coalition

## Foreign currency

### *Functional currency*

Items included in the financial statements of the Foundation are valued with due regard for the currency in the economic environment in which the Foundation carries out most of its activities (the functional currency). The financial statements are denominated in euros; this is both the functional currency and presentation currency of the Foundation.

### *Transactions, receivables and liabilities*

Transactions in foreign currencies are stated in the financial statements at the exchange rate of the functional currency on the transaction date.

Monetary assets and liabilities in foreign currencies are converted to the closing rate of the functional currency on the balance sheet date. The translation differences resulting from settlement and conversion are credited or charged to the income statement, unless hedge-accounting is applied.

Non-monetary assets valued at historical cost in a foreign currency are converted at the exchange rate on the transaction date.

## ACCOUNTING POLICIES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

### **Accounts receivable**

The receivables are initially recognised at the fair value and subsequently valued at amortised costs. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. The provisions are determined based on individual assessment of the receivables.

### **Securities**

Listed securities that are held for trading are carried at current value (fair value). The fair value of listed securities is the same as the market price. Listed bonds that are not held for trading are measured at amortised cost. Securities other than listed securities are valued at historical cost or lower fair value. In the latter situation, the fair value is estimated in accordance with generally accepted valuation models and techniques. Fair value gains of securities measured at fair value are directly recognised in the profit and loss account. Fair value losses of securities measured at fair value are also directly recognised in the profit and loss account. Transaction costs directly attributable to the acquisition of securities are directly recognised in the profit and loss account.

### **Cash at bank and in hand**

Cash at bank and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at bank and in hand is carried at nominal value.

### **Current liabilities**

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received, taking into account premiums or discounts, less transaction costs. This usually is the nominal value.

### **Reserves**

#### *Unrestricted reserves*

The Foundation has unrestricted reserves, which may be freely spent within the statutory objectives of the organisation. Amendments on the unrestricted reserves are done through the results allocation of the statement of income and expenditure.

#### *Restricted Reserves*

The Foundation has Restricted reserves, which have a more limited designation than the Unrestricted Reserves. The limitation of the reserves is imposed by the Board of Directors. Amendments on the Restricted reserves are done through the result allocation of the statement of income and expenditure.

# Stichting International Kidney Cancer Coalition

## PRINCIPLES FOR THE DETERMINATION OF THE RESULT

### General

The surplus or deficit is determined as the difference between the total income and total expenses of the year to which they relate.

### Income

The income of the Foundation is recorded and recognized in the period in which the income has been effectuated. The effectuation is determined based on the sponsorship period or the realization of events.

### Expense

The expenses of the Foundation are determined on a historical basis and are attributed to the reporting year to which they relate.

### Interest income and interest expenses

Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

### Dividends

Dividends to be received from participations and securities not carried at net asset value are recognised as soon as the company has acquired the right to them.

## PRINCIPLES FOR THE PREPARATION OF THE CASH-FLOW STATEMENT

### Accounting policies for the cash flow statement

The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flow denominated in foreign currencies have been translated at average estimated exchange rates.

Interest paid and received, dividends received, and income taxes are included in cash from operating activities.

# Stichting International Kidney Cancer Coalition

## 2.5. Notes to the balance sheet

### ASSETS

#### CURRENT ASSETS

##### Receivables

	<u>31-Dec-24</u>	<u>31-Dec-23</u>
	€	€
<b>Other prepayments and accrued income</b>		
Cost paid up in front	65,159	--
Amounts receivable	<u>2,566</u>	<u>3,006</u>
	<u><u>67,725</u></u>	<u><u>3,006</u></u>

	<u>31-Dec-24</u>	<u>31-Dec-23</u>
	€	€
<b>Securities</b>		
ING Investment account	<u>682,367</u>	<u>637,822</u>

	<u>31-Dec-24</u>	<u>31-Dec-23</u>
	€	€
<b>Cash at bank and in hand</b>		
ING US Dollar account	228,260	497,162
ING reserve operating account	201,956	201,714
ING payment account	<u>20,043</u>	<u>30,612</u>
	<u><u>450,259</u></u>	<u><u>729,488</u></u>

2.5. Notes to the balance sheet

LIABILITIES

Foundation's capital

	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves World Kidney Cancer Day</b>		
Value as of 1 January	150,000	185,000
Utilization	(126,689)	(197,067)
From/ to unrestricted reserves	96,689	162,067
Value as of 31 December	<b>120,000</b>	<b>150,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Global Kidney Cancer Summit</b>		
Value as of 1 January	140,000	125,000
Utilization	(142,375)	(157,220)
From/ to unrestricted reserves	142,375	172,220
Value as of 31 December	<b>140,000</b>	<b>140,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves PAG Incubator</b>		
Value as of 1 January	50,000	100,000
Utilization	--	--
From/ to unrestricted reserves	(50,000)	(50,000)
Value as of 31 December	<b>--</b>	<b>50,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Dashboard Project</b>		
Value as of 1 January	--	44,000
Utilization	(1,694)	(2,214)
From/ to unrestricted reserves	3,694	(41,786)
Value as of 31 December	<b>2,000</b>	<b>--</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Global Patient Survey</b>		
Value as of 1 January	--	42,000
Utilization	--	(8,375)
From/ to unrestricted reserves	--	(33,625)
Value as of 31 December	<b>--</b>	<b>--</b>

## Stichting International Kidney Cancer Coalition

### 2.5. Notes to the balance sheet

	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Decision Aid: Best Supportive Care</b>		
Value as of 1 January	25,000	25,000
Utilization	(25,660)	(26,184)
From/ to unrestricted reserves	660	26,184
Value as of 31 December	--	<b>25,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Clinical Leadership Develop. Workshop</b>		
Value as of 1 January	50,000	50,000
Utilization	(20,171)	(12,729)
From/ to unrestricted reserves	(29,829)	12,729
Value as of 31 December	--	<b>50,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Kidney Cancer Advocacy Feas. Study</b>		
Value as of 1 January	--	15,000
Utilization	--	(3,365)
From/ to unrestricted reserves	--	(11,635)
Value as of 31 December	--	--
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Global Patient Survey 2024</b>		
Value as of 1 January	90,000	--
Utilization	(107,605)	--
From/ to unrestricted reserves	17,605	90,000
Value as of 31 December	--	<b>90,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves CAB</b>		
Value as of 1 January	10,000	--
Utilization	--	--
From/ to unrestricted reserves	(10,000)	10,000
Value as of 31 December	--	<b>10,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Seed and Grow</b>		
Value as of 1 January	--	--
Utilization	(2,241)	--
From/ to unrestricted reserves	2,241	--
Value as of 31 December	--	--

# Stichting International Kidney Cancer Coalition

## 2.5. Notes to the balance sheet

	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves SDM Analysis 2024</b>		
Value as of 1 January	20,000	--
Utilization	(14,457)	--
From/ to unrestricted reserves	55,238	20,000
Value as of 31 December	<b>60,781</b>	<b>20,000</b>
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves RCC Perisurgical TC (RCC-PTC) meeting 2024</b>		
Value as of 1 January	--	--
Utilization	--	--
From/ to unrestricted reserves	60,000	--
Value as of 31 December	<b>60,000</b>	--
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves Interact Europe 100</b>		
Value as of 1 January	--	--
Utilization	--	--
From/ to unrestricted reserves	1,000	--
Value as of 31 December	<b>1,000</b>	--
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves DISCERN</b>		
Value as of 1 January	--	--
Utilization	(1,246)	--
From/ to unrestricted reserves	60,500	--
Value as of 31 December	<b>59,254</b>	--
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Restricted reserves CARE1</b>		
Value as of 1 January	--	--
Utilization	(3,824)	--
From/ to unrestricted reserves	14,500	--
Value as of 31 December	<b>10,676</b>	--
	<b>31-Dec-24</b>	<b>31-Dec-23</b>
	€	€
<b>Unrestricted reserves</b>		
Value as of 1 January	774,167	700,251
To restricted reserves	(364,673)	(356,154)
Operating result	249,032	430,070
Value as of 31 December	<b>658,526</b>	<b>774,167</b>

# Stichting International Kidney Cancer Coalition

## 2.5. Notes to the balance sheet

### CURRENT LIABILITIES

	<u>31-Dec-24</u>	<u>31-Dec-23</u>
	€	€
<b>Accounts payable</b>		
Creditors	<u>60,321</u>	<u>33,279</u>
	<u>31-Dec-24</u>	<u>31-Dec-23</u>
	€	€
<b>Accruals and other payables</b>		
Payable costs	27,142	27,870
Credit cards	651	--
	<u>27,793</u>	<u>27,870</u>

# Stichting International Kidney Cancer Coalition

## 2.6. Notes to the statement of income and expenditure

	<u>2024</u>	<u>2023</u>
	€	€
<b>Net turnover</b>		
Sustaining partnerships	357,615	176,358
Projects	<u>262,560</u>	<u>640,255</u>
	<b><u>620,175</u></b>	<b><u>816,613</u></b>

The net turnover of 2024 decreased by -24% versus prior year.

	<u>2024</u>	<u>2023</u>
	€	€
<b>Expenditure</b>		
Objective 1: To strengthen the capacity of current and emerging affiliates in their support for patients with kidney cancer.	234,333	243,745
Objective 2: To advocate for access to best care	126,906	116,228
Objective 3: To increase awareness of kidney cancer globally	192,213	262,979
Objective 4: To be a global authority in the provision of credible and up-to-date kidney cancer information.	120,914	119,838
Objective 5: To foster projects promoting the voice of kidney cancer patients in research activities worldwide.	207,683	88,336
	<b><u>882,049</u></b>	<b><u>831,126</u></b>

	<u>2024</u>	<u>2023</u>
	€	€
<b>Financial income &amp; expenses</b>		
Investment account result	44,545	55,330
Foreign currency exchange result	19,442	(19,226)
ING bank interest income	957	1,325
	<b><u>64,944</u></b>	<b><u>37,429</u></b>